Neal J Harte Net Worth

The estimated Net Worth of Neal J Harte is at least $301 mil dollars as of 25 May 2016. Neal Harte owns over 6,589 units of Harvard Bioscience stock worth over $301,109 and over the last 21 years Neal sold HBIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Neal Harte HBIO stock SEC Form 4 insiders trading

Neal has made over 4 trades of the Harvard Bioscience stock since 2014, according to the Form 4 filled with the SEC. Most recently Neal exercised 6,589 units of HBIO stock worth $19,833 on 25 May 2016.

The largest trade Neal's ever made was exercising 26,352 units of Harvard Bioscience stock on 5 August 2014 worth over $56,657. On average, Neal trades about 2,478 units every 37 days since 2004. As of 25 May 2016 Neal still owns at least 106,399 units of Harvard Bioscience stock.

You can see the complete history of Neal Harte stock trades at the bottom of the page.

What's Neal Harte's mailing address?

Neal's mailing address filed with the SEC is 83 Church St #1, Winchester, MA 01890, USA.

Insiders trading at Harvard Bioscience

Over the last 21 years, insiders at Harvard Bioscience have traded over $10,145,146 worth of Harvard Bioscience stock and bought 754,658 units worth $2,380,232 . The most active insiders traders include Earl R Lewis, Bertrand Loy, eDavid Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of $182,054. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth $29,100.

What does Harvard Bioscience do?

harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.

Complete history of Neal Harte stock trades at Harvard Bioscience

Harvard Bioscience executives and stock owners

Harvard Bioscience executives and other stock owners filed with the SEC include:

• James Green,
  Chairman of the Board, President, Chief Executive Officer
• James W. Green,
  Pres, CEO & Chairman
• Kenneth Fletcher Olson,
  Chief Operating Officer
• Michael A. Rossi,
  Chief Financial Officer
• Michael Rossi,
  Chief Financial Officer
• Bertrand Loy,
  Lead Independent Director
• John Kennedy,
  Independent Director
• Alan Edrick,
  Independent Director
• Thomas Loewald,
  Independent Director
• Katherine Eade,
  Independent Director
• Susan Steele,
  Independent Director
• Kenneth Olson,
  Vice President, General Manager - Data Sciences International
• David Sirois,
  Director of Corp. Accounting & SEC Reporting
• Jacques Coumans Ph.D.,
  Chief Marketing Officer
• David Green,
  President
• Earl R Lewis,
  Director
• Robert E. Gagnon,
  Chief Financial Officer
• Neal J Harte,
  Director
• George Uveges,
  Director
• Jeffrey Duchemin,
  Chief Executive Officer
• Yong Sun,
  VP - Strategic Marketing
• Kamalam Unninayar,
  Chief Financial Officer
• David L Strack,
  President of Subsidiary
• Chane Graziano,
  Chief Executive Officer
• Robert A Dishman,
  Director
• Yoav Sibony,
  VP - Global Sales
• Thomas Mc Naughton,
  Chief Financial Officer
• Mark A Norige,
  Chief Operating Officer
• Paul Bailey,
  Vice President Finance
• Bryce Anthony Chicoyne,
  Chief Financial Officer
• Advisors Llc Nelson Kerry S...,
  
• Limited Partnership Hso,
  10% owner
• Susan M Luscinski,
  Chief Financial Officer
• Yash Singh,
  Executive Vice President
• Jennifer Cote,
  Chief Financial Officer